Finance

Lists
Why is XGN up 3,55%?
Dive Deeper
XGN:NASDAQ
Exagen Inc
USD 8,17
+3,55%
(+0,28) 1D
USD 8,16
-0,12% (-0,010)
After hours
Closed: 2 Okt., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for XGN...
Open
USD 7,99
High
USD 8,20
Low
USD 7,78
Mkt. cap
197,92 m
Avg. vol.
271,68 k
Volume
617,37 k
52-wk high
USD 12,23
52-wk low
USD 2,60
EPS
-USD 0,81
Beta
2,12
Shares outstanding
24,22 m
No. of employees
218
Open
USD 7,99
High
USD 8,20
Low
USD 7,78
Mkt. cap
197,92 m
Avg. vol.
271,68 k
Volume
617,37 k
52-wk high
USD 12,23
52-wk low
USD 2,60
EPS
-USD 0,81
Beta
2,12
Shares outstanding
24,22 m
No. of employees
218
News stories
From web sources and news partners
About Exagen Inc
CEO-
Employees218
Founded2002
HeadquartersVista, Kalifornië, Verenigde State van Amerika
Sector-
Websiteexagen.com
Analyst ratings
Based on 5 analysts giving stock ratings to XGN in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for XGN in the last 3 months.
Highest
Current USD 8,17
USD 12,00 (+46,88%)
Average
USD 10,20 (+24,85%)
Lowest
USD 9,00 (+10,16%)
Analyst
Recommendation
Action
Price target
Projected
Date
Max Masucci
Roth MKM
Buy
Maintained
USD 11,00
+34,6%
09/22/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
USD 12,00
+46,9%
09/11/2026
Anderson Schock
B. Riley Securities
Buy
Reiterated
USD 12,00
+46,9%
08/05/2026
Mark Massaro
BTIG
Buy
Reiterated
USD 9,00
+10,2%
08/05/2026
Kyle Mikson CFA
Canaccord Genuity
Buy
Maintained
USD 9,00
+10,2%
08/05/2026
Daniel Brennan
TD Cowen
Buy
Reiterated
USD 10,00
+22,4%
08/04/2026
Unknown Analyst
Roth MKM
Buy
Initiated
USD 8,00
-2,1%
06/24/2026
Andrew Brackmann
William Blair
Buy
Reiterated
-
-
05/12/2026
William Bonello
Craig-Hallum
Buy
Reiterated
USD 10,00
+22,4%
03/11/2026
Paul Knight
KeyBanc
Buy
Maintained
USD 10,00
+22,4%
03/11/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
17,24 m
16,63 m
17,31 m
19,94 m
Cost of goods sold
7,17 m
7,42 m
7,10 m
7,72 m
Cost of revenue
7,17 m
7,42 m
7,10 m
7,72 m
Research and development expenses
1,73 m
1,76 m
1,55 m
1,43 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11,44 m
12,42 m
12,07 m
12,51 m
Operating expense
13,18 m
14,18 m
13,62 m
13,94 m
Total operating expenses
20,34 m
21,61 m
20,72 m
21,66 m
Operating income
-3,10 m
-4,98 m
-3,41 m
-1,72 m
Other non operating income
-
-
-132,00 k
153,00 k
EBT including unusual items
-7,09 m
-4,66 m
-3,93 m
-3,20 m
EBT excluding unusual items
-4,42 m
-6,26 m
-4,81 m
-2,77 m
Income tax expense
1,00 k
13,00 k
36,00 k
-
Effective tax rate
-0,01%
-0,28%
-0,92%
-
Other operating expenses
-
-
-
-
Net income
-7,09 m
-4,67 m
-3,97 m
-3,20 m
Net profit margin
-41,10%
-28,10%
-22,92%
-16,03%
Earnings per share
-0,31
-0,27
-0,20
-0,11
Interest and investment income
3,00 k
43,00 k
-
-
Interest expense
-1,32 m
-1,33 m
-1,27 m
-1,20 m
Net interest expenses
-1,32 m
-1,29 m
-1,27 m
-1,20 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-2,49 m
-4,38 m
-2,82 m
-1,09 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme